Form 4: Spyre Therapeutics CEO Sells Shares Under 10b5-1 Plan

Spyre Therapeutics CEO Cameron Turtle sold 15,000 shares of common stock on February 2, 2026, as part of a pre-arranged 10b5-1 trading plan.

Summary

• Cameron Turtle, Chief Executive Officer and Director of Spyre Therapeutics, Inc. (SYRE), reported sales of common stock.
• A total of 15,000 shares were sold on February 2, 2026, under a Rule 10b5-1 trading plan adopted on June 20, 2025.
• The sales occurred in two transactions: 957 shares at a weighted average price of $31.82 and 14,043 shares at a weighted average price of $32.87.
• Following these transactions, Cameron Turtle beneficially owns 657,540 shares of common stock.
• This beneficial ownership includes 145,198 shares that vest in monthly installments over approximately one year, subject to continued service.
• It also includes 633 shares acquired through the Issuer's 2016 Employee Stock Purchase Plan on August 15, 2024.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral event. While an insider sale, its execution under a pre-arranged 10b5-1 plan mitigates concerns of negative sentiment, suggesting planned financial management rather than a reaction to adverse company news.

Positives

• The sales were executed under a Rule 10b5-1 trading plan, indicating pre-planning and potentially reducing concerns about opportunistic insider selling.

Negatives

• Cameron Turtle, a key executive and director, sold 15,000 shares of company common stock.

Risks

• While mitigated by the 10b5-1 plan, insider sales can sometimes be perceived by the market as a lack of confidence, potentially leading to short-term negative sentiment.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

StockSavvy.ai notes that insider sales executed under Rule 10b5-1 plans are a common practice among corporate executives for personal financial planning, such as diversification or liquidity needs. These pre-arranged plans are designed to allow insiders to sell shares without being accused of trading on material non-public information, thereby distinguishing them from opportunistic sales.

Corporate Governance

Stakeholder Impact

• Shareholders: May observe the insider sale, but the 10b5-1 plan context should provide reassurance that it is a planned financial event rather than a signal of declining company prospects.

Next Steps

• The filing indicates that 145,198 shares of common stock will continue to vest in monthly installments over approximately one year, subject to the Reporting Person's continuing service.

Key Dates

Recommendation

The insider sales by CEO Cameron Turtle were conducted under a pre-established Rule 10b5-1 trading plan. This type of transaction is generally considered a routine personal financial management activity (e.g., diversification, liquidity) and does not typically signal a change in the company's fundamental outlook or warrant an immediate shift in investment strategy. Therefore, a 'hold' recommendation is appropriate, maintaining current positions while monitoring future company developments.

Keywords

Spyre Therapeutics, SYRE, Cameron Turtle, CEO, Director, Form 4, insider trading, stock sale, 10b5-1 plan, equity transaction